Craig Eagle

10.0k total citations · 2 hit papers
26 papers, 1.6k citations indexed

About

Craig Eagle is a scholar working on Pharmacology, Surgery and Oncology. According to data from OpenAlex, Craig Eagle has authored 26 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pharmacology, 9 papers in Surgery and 9 papers in Oncology. Recurrent topics in Craig Eagle's work include Inflammatory mediators and NSAID effects (15 papers), Genetic factors in colorectal cancer (5 papers) and Helicobacter pylori-related gastroenterology studies (5 papers). Craig Eagle is often cited by papers focused on Inflammatory mediators and NSAID effects (15 papers), Genetic factors in colorectal cancer (5 papers) and Helicobacter pylori-related gastroenterology studies (5 papers). Craig Eagle collaborates with scholars based in United States, Israel and Australia. Craig Eagle's co-authors include Ann G. Zauber, Bernard Levin, Nadir Arber, Scott D. Solomon, Janet Wittes, Rebecca B. Rosenstein, María José Lechuga, Julius Špičák, I Rácz and Miroslav Zavoral and has published in prestigious journals such as New England Journal of Medicine, Circulation and Journal of Clinical Oncology.

In The Last Decade

Craig Eagle

24 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Celecoxib for the Prevention of Colorectal Adenomatous Polyps

2006 751 citations Nadir Arber, Craig Eagle et al. New England Journal of Medicine profile →
A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening

2024 163 citations Daniel C. Chung, Darrell M. Gray et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Craig Eagle United States	13	749	536	299	268	254	26	1.6k
Jan Hajer Czechia	10	434 0.6×	359 0.7×	160 0.5×	258 1.0×	166 0.7×	24	1.0k
Paola Gerletti United States	6	467 0.6×	335 0.6×	172 0.6×	159 0.6×	190 0.7×	9	915
Michelle Wilson United Kingdom	5	942 1.3×	839 1.6×	695 2.3×	357 1.3×	455 1.8×	7	2.4k
Elizabeth Half Israel	19	519 0.7×	800 1.5×	359 1.2×	510 1.9×	607 2.4×	49	2.2k
Kouji Watanabe Japan	14	757 1.0×	190 0.4×	197 0.7×	214 0.8×	279 1.1×	51	1.3k
Rikio Yoshimura Japan	23	576 0.8×	230 0.4×	410 1.4×	198 0.7×	772 3.0×	75	1.8k
Kouichi Kurose Japan	22	636 0.8×	489 0.9×	123 0.4×	117 0.4×	661 2.6×	54	2.0k
Mingxin Che United States	25	215 0.3×	582 1.1×	440 1.5×	255 1.0×	703 2.8×	36	1.9k
José M. Ladero Spain	27	256 0.3×	386 0.7×	177 0.6×	116 0.4×	580 2.3×	72	1.9k
E.L. Levine United Kingdom	11	445 0.6×	481 0.9×	290 1.0×	229 0.9×	351 1.4×	17	1.4k

Countries citing papers authored by Craig Eagle

Since Specialization

Citations

This map shows the geographic impact of Craig Eagle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Craig Eagle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Craig Eagle more than expected).

Fields of papers citing papers by Craig Eagle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Craig Eagle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Craig Eagle. The network helps show where Craig Eagle may publish in the future.

Co-authorship network of co-authors of Craig Eagle

This figure shows the co-authorship network connecting the top 25 collaborators of Craig Eagle. A scholar is included among the top collaborators of Craig Eagle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Craig Eagle. Craig Eagle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Raymond, Victoria M., et al.. (2025). Cost-effectiveness of blood-based colorectal cancer screening – a simulation model incorporating real-world longitudinal adherence. Expert Review of Pharmacoeconomics & Outcomes Research. 25(5). 671–677.

Sharif, Behnam, Gabriel Tremblay, Victoria M. Raymond, et al.. (2024). Population health outcomes of blood-based screening for colorectal cancer in comparison to current screening modalities: insights from a discrete-event simulation model incorporating longitudinal adherence. Journal of Medical Economics. 27(1). 991–1002. 1 indexed citations

Das, Amar K., et al.. (2024). AI-generated synthetic clinical-genomic data for precision oncology research: Validation using a case study on lung adenocarcinoma.. Journal of Clinical Oncology. 42(16_suppl). e13627–e13627. 1 indexed citations

Raymond, Victoria M., et al.. (2023). Screening for high frequency malignant disease (SHIELD).. Journal of Clinical Oncology. 41(16_suppl). TPS1610–TPS1610. 1 indexed citations

Chung, Daniel C., Darrell M. Gray, Joel K. Greenson, et al.. (2023). 913e CLINICAL VALIDATION OF A CELL-FREE DNA BLOOD-BASED TEST FOR COLORECTAL CANCER SCREENING IN AN AVERAGE RISK POPULATION. Gastroenterology. 164(6). S–1573. 6 indexed citations

Raymond, Victoria M., et al.. (2022). Screening for high frequency malignant disease (SHIELD).. Journal of Clinical Oncology. 40(16_suppl). TPS1602–TPS1602. 2 indexed citations

Arber, Nadir, David A. Lieberman, Timothy C. Wang, et al.. (2012). The APC and PreSAP Trials: A Post Hoc Noninferiority Analysis Using a Comprehensive New Measure for Gastrointestinal Tract Injury in 2 Randomized, Double-Blind Studies Comparing Celecoxib and Placebo. Clinical Therapeutics. 34(3). 569–579. 5 indexed citations

Sabichi, Anita L., J. Jack Lee, H. Barton Grossman, et al.. (2011). A Randomized Controlled Trial of Celecoxib to Prevent Recurrence of Nonmuscle-Invasive Bladder Cancer. Cancer Prevention Research. 4(10). 1580–1589. 42 indexed citations

Huang, Kui, Lia Gutiérrez, Steffen Bülow, et al.. (2011). Clinical characteristics and outcomes in familial adenomatous polyposis patients with a long-term treatment of celecoxib: a matched cohort study. Familial Cancer. 10(2). 303–308. 14 indexed citations

10.

Arber, Nadir, Julius Špičák, I Rácz, et al.. (2011). Five-Year Analysis of the Prevention of Colorectal Sporadic Adenomatous Polyps Trial. The American Journal of Gastroenterology. 106(6). 1135–1146. 59 indexed citations

11.

Lynch, Patrick M., Gregory D. Ayers, Ellen Richmond, et al.. (2010). The Safety and Efficacy of Celecoxib in Children With Familial Adenomatous Polyposis. The American Journal of Gastroenterology. 105(6). 1437–1443. 57 indexed citations

12.

Bertagnolli, Monica M., Meier Hsu, Ernest T. Hawk, Craig Eagle, & Ann G. Zauber. (2010). Statin Use and Colorectal Adenoma Risk: Results from the Adenoma Prevention with Celecoxib Trial. Cancer Prevention Research. 3(5). 588–596. 28 indexed citations

13.

Chan, Andrew T., Ann G. Zauber, Meier Hsu, et al.. (2009). Cytochrome P450 2C9 Variants Influence Response to Celecoxib for Prevention of Colorectal Adenoma. Gastroenterology. 136(7). 2127–2136.e1. 41 indexed citations

14.

Cho, Nancy L., Mark Redston, Ann G. Zauber, et al.. (2008). Aberrant Crypt Foci in the Adenoma Prevention with Celecoxib Trial. Cancer Prevention Research. 1(1). 21–31. 46 indexed citations

15.

Arber, Nadir, Julius Špičák, I Rácz, et al.. (2008). Chemopreventive Effectiveness of Celecoxib Two Years After Cessation of Treatment. Gastroenterology. 135(1). 295–296. 1 indexed citations

16.

Chan, Andrew T., Ann G. Zauber, Craig Eagle, et al.. (2008). W1104 The Influence of Genetic Variation in the Cytochrome P450 2c9 Enzyme in a Randomized Trial of Celecoxib for the Prevention of Sporadic Colorectal Adenoma. Gastroenterology. 134(4). A–634. 1 indexed citations

17.

Arber, Nadir, Craig Eagle, Julius Špičák, et al.. (2006). Celecoxib for the Prevention of Colorectal Adenomatous Polyps. New England Journal of Medicine. 355(9). 885–895. 751 indexed citations breakdown →

18.

Solomon, Scott D., Marc A. Pfeffer, John J.V. McMurray, et al.. (2006). Effect of Celecoxib on Cardiovascular Events and Blood Pressure in Two Trials for the Prevention of Colorectal Adenomas. Circulation. 114(10). 1028–1035. 206 indexed citations

19.

Nelson, Margaret, et al.. (2001). Genotyping fetal DNA by non‐invasive means: extraction from maternal plasma. Vox Sanguinis. 80(2). 112–116. 39 indexed citations

20.

Berdoukas, Vasili, et al.. (2000). The Sydney Children's Hospital experience with the oral iron chelator deferiprone (L1). Transfusion Science. 23(3). 239–240. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact